Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The new site is focused on providing early-stage R&D services including chemical process development, pre-formulation study and formulation development.
December 21, 2022
By: Charlie Sternberg
Asymchem Laboratories (Tianjin) Co. Ltd., a CDMO serving the global pharmaceutical and biotech industry, has opened a new site in Woburn, Massachusetts. Asymchem Boston, a wholly owned subsidiary of Asymchem Group, marks an important step toward expanding Asymchem’s global footprint. The new Boston site is focused on providing early-stage R&D services including chemical process development, pre-formulation study and formulation development for small molecules, peptides and oligonucleotides. After establishing the location in August 2022, the site is now ready for full operation. Currently there is 6000 sqft of existing lab space that includes process and analytical labs, and space to expand in an additional 4500 sqft. Solid characterization and pre-formulation labs will be ready in Q1 2023. By Q3 2023 continued expansion will include a fully functional kilo-lab, formulation R&D, and oligonucleotide and peptide lab to support drug substance and drug product development and non-GMP production. Asymchem Boston not only provides direct service to biotech clients, but also serves as a liaison between its China-based manufacture sites and the company’s partners. Though the site’s current focus is on small molecules, it will soon engage with more oligonucleotide and peptide work within the next year. From medicinal chemistry support to IND-enabling, the site will be equipped with the capacity to assist in early-stage process development for both drug substance and drug product. “Asymchem has been working diligently in recent years to bring biotech clients an even more well-rounded CMC experience when managing early-stage projects. The company’s expansion to Boston has become an integral part of this journey to better serve Asymchem’s national and global partners,” said Dr. Hao Hong, chief executive officer of Asymchem Group.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !